To uncover the compensatory GF signal-mediated proliferation phenotype of these endocrine + CDK4/6i-resistant cancer cells, we profiled tumors of a much larger cohort of patients (the discovery and validation cohorts). This evidence concerns the gene CDK4 and cancer.